DXB Dimerix Ltd
- 0.340
- 0.0000.00%
Dimerix Ltd News
Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication
Dimerix (ASX:DXB) secured approval from the UK Medicines and Healthcare Products Regulatory Agency for the pediatric investigation plan for its kidney disease medication DMX-200, according to a Wednes
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter
Dimerix (ASX:DXB) has reported AU$35.2 million in cash and AU$3.3 million of operating cash outflows for the quarter ended March 31, mostly from clinical and CMC costs related to its Phase 3 FSGS stud
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target
04:35 AM EDT, 04/19/2024 (MT Newswires) -- Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target
Dimerix Initiated at Speculative Buy by Euroz Hartleys
Dimerix Initiated at Speculative Buy by Euroz Hartleys
Dimerix With Proactive at ASX Small and Mid Cap Conference | ASX:DXB, OTC:SBMJF
Dimerix Raises AU$20 Million for Kidney Disease Study
Dimerix (ASX:DXB) raised AU$20 million via an institutional placement of 66,666,667 ordinary shares at AU$0.30 apiece. Proceeds will be used to complete the ACTION3 phase three clinical study in patie
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better Than Placebo
Dimerix (ASX:DXB) said it will expand its kidney drug study after DMX-200 performed better than the placebo in reducing proteinuria. Phase three trial achieved success in its pre-specified interim ana
Calculating The Intrinsic Value Of Dimerix Limited (ASX:DXB)
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%
Dimerix (ASX:DXB) secured an investigational new drug approval for the DMX-200 medication from the Chinese National Medical Products Administration's Center for Drug Evaluation, according to a Tuesday
Dimerix Appoints Nonexecutive Chair
Biopharmaceutical company Dimerix (ASX:DXB) appointed Mark Diamond as nonexecutive chair, effective Dec. 1. In May, Diamond retired from Antisense Therapeutics (ASX:ANP) as managing director and chief
Shareholders Will Likely Find Dimerix Limited's (ASX:DXB) CEO Compensation Acceptable
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights
Dimerix (ASX:DXB) received the initial upfront payment of AU$10.7 million from Advanz Pharma for the exclusive rights to commercialize DMX-200 in the European Economic Area, the UK, Switzerland, Canad
Dimerix Appoints Medical Chief
Dimerix (ASX:DXB) appointed David Fuller as chief medical officer, succeeding Ash Soman. Fuller is the chair of diagnostic company EpiAxis Therapeutics and nonexecutive director of biotech company, Ad
Softer US Employment Data End Australian Shares' Three-Day Losing Streak
Australian shares ended their three-day losing streak, rebounding on Thursday as concerns over the US Federal Reserve hiking rates further eased amid softer US employment data. The S&P/ASX 200 Index r
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug
Dimerix (ASX:DXB) shares surged 154% in recent trade after the company secured a licensing deal for its kidney disease drug. The company entered into an exclusive license agreement with Advanz Pharma
Stocks of the Hour: Vintage Energy, Rumble Resources, QX Resources, Dimerix, BluGlass
Vintage Energy (ASX:VEN) announces an additional two-year gas sale under the master gas supply agreement for the Odin gas field. The joint venture parties have agreed and signed terms with Pelican Poi
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name
Dimerix (ASX:DXB) secured conditional clearance from the US Food and Drug Administration for the use of Qytovra as the commercial brand name of the biopharmaceutical firm's medication candidate former
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia
Dimerix (ASX:DXB) secured regulatory approval from the Malaysian National Pharmaceutical Regulatory Agency to conduct a phase 3 trial in the country, the biopharmaceutical firm said on Friday. The stu
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%
Dimerix (ASX:DXB) secured AU$8.9 million of tax rebate for the fiscal year ended June 30 as part of the Australian government's research and development tax incentive scheme. Part of the proceeds will
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe
Dimerix (ASX:DXB) secured approval from the European Medicines Agency for its pediatric investigation plan for the potential use of its medication DMX-200 in children with focal segmental glomerulosclerosis.
Analysis
Price Target
No Data
